Calculate your potential ROI with ACT

Tested in over 300 breast health clinics across the US, ACT has proven results across the board(1,2). Input your Total Annual Screenings to estimate the ROI ACT can have at your clinic.

Increase breast cancer screening compliance rates

Improve radiologists’ accuracy, productivity, and workflow

Optimize clinic operations to ensure patients receive timely and compassionate care

Total Annual Screenings

Calculate

Estimated ROI

0
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
0

This calculation is based on a global average screening reimbursement of $205 and is for estimation purposes only. Actual results will vary.

Footnotes

1. Compared to a previous average of about 1% or less growth per year.
2. Average growth rate across all clinics using ACT.

Products

ACT
ACT ROI
WRDensity
WRRisk
Request a Demo

Company

AboutOur TeamCareersContact

Privacy Policy

End User Agreement

Copyright © , Whiterabbit.ai

Compliance Improvement Software

‍

ACT is our AI-powered software solution designed to dramatically increase breast cancer screening compliance.

What if we could ensure that every eligible woman gets her routine screening mammogram?

Find out how ACT can help do just that.

Play Video
How It Works

Driving an average of 20% year-over-year growth in screening exam volumes in over 300 breast health clinics and growing across the US since launching in 2018.

ACT ingests and analyzes key demographic data points for each eligible patient¹ and automatically generates a targeted outreach strategy proven to motivate the individual to schedule their screening mammogram.

Agents trained on the ACT program are equipped with accurate, actionable information and our powerful algorithm-driven outreach strategy to increase mammography compliance.

Whiterabbit has helped RadNet to better mine our data, allowing us to significantly enhance patient compliance with screening mammography guidelines and to more accurately measure our screening capacity and expansion opportunities.  They have been a valued business partner in our efforts to create enhanced awareness of breast cancer screening and in growing our mammography volume.

‍

Stephen M. Forthuber
President and Chief Operating Officer
Eastern Operations

‍

‍

Whiterabbit has helped RadNet to better mine our data, allowing us to significantly enhance patient compliance with screening mammography guidelines and to more accurately measure our screening capacity and expansion opportunities.  They have been a valued business partner in our efforts to create enhanced awareness of breast cancer screening and in growing our mammography volume.

‍

Stephen M. Forthuber
President and Chief Operating Officer
Eastern Operations

‍

‍

Unique Features

Increase revenue. Increase patient compliance. Improve outcomes.

‍

Our proprietary AI-powered software was trained on millions of data points, designed to motivate the user to action.

Intelligent from start to finish.

‍

ACT’s robust data analytics provide a range of powerful insights to our clients about their mammography program.

‍

Growth that scales.

‍

ACT software dynamically scales to meet increasing volumes without requiring laborious 1:1 follow-ups.

‍

Find out how our products can help your business increase compliance, increase revenue and improve outcomes.

Request A Demo
News & Research
News
RadNet and Whiterabbit.ai Form a Comprehensive Partnership to Address Mammography Compliance and Improved Diagnostics for Breast Cancer
Read More
View More
News & Research
No items found.
View More
News & Research
Research
A Multi-site Study of a Breast Density Deep Learning Model for FFDM and DBT
Read More
Research
A Hypersensitive Breast Cancer Detector - Oral presentation at the SPIE Medical Imaging Conference 2020
Read More
View More
Footnotes

1 Eligible patient is defined as any woman who has a screening mammogram within the previous five years.

2 Moorman S, Pujara A, Sakala M, et al. Annual Screening Mammography Associated With Lower Stage Breast Cancer Compared With Biennial Screening. American Journal of Roentgenology 2021 217:1, 40-47

Products

ACT
ACT ROI
WRDensity
WRRisk
Request a Demo

Company

AboutOur TeamCareersContact

Privacy Policy

End User Agreement

Copyright © , Whiterabbit.ai